Bryan Sclerosol for prevention of recurrent malignant pleural effusion to be launched by March.

BRYAN SCLEROSOL FOR MALIGNANT PLEURAL EFFUSIONS SET FOR LAUNCH BY MARCH, the Woburn-Mass.-based company said following FDA approval of the intrapleural aerosol talc product Dec. 24. Sclerosol is indicated for use during thoracoscopy or open thoracotomy "to prevent recurrence of malignant pleural effusions in symptomatic patients."